Logo image
Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: A case report
Journal article   Peer reviewed

Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: A case report

Suthee Rapisuwon, Kellie Parks, Waddah Al-Refaie and Michael B. Atkins
Melanoma Research, Vol.24(5)
2014

Abstract

Antineoplastic Agents Benzamides Biopsy DNA Mutational Analysis Exons Fatal Outcome Female Humans Melanoma Middle Aged Mucous Membrane Mutation Neoplasm Metastasis Piperazines Proto-Oncogene Proteins c-kit Pyrimidines Skin Neoplasms Stem Cell Factor corticosteroid imatinib ipilimumab melan A monoclonal antibody HMB 45 protein S 100 antineoplastic agent benzamide derivative imatinib piperazine derivative pyrimidine derivative stem cell factor stem cell factor receptor adult Article asthenia case report central nervous system metastasis colitis computer assisted tomography confusion drug response endoscopic biopsy exon female herbal medicine hospice care human human tissue immunohistochemistry leg edema liver metastasis lung metastasis melanoma middle aged mutational analysis oncogene c kit paranasal sinus tumor paresthesia priority journal single nucleotide polymorphism sinonasal mucosal melanoma sinus congestion somatic mutation weight reduction biopsy exon fatality genetics melanoma metabolism metastasis mucosa mutation nucleotide sequence pathology Skin Neoplasms
Primary mucosal melanomas represent ∼1.3% of all cases of melanoma diagnosed in the USA. The sinonasal location is the most common primary site. Mutations in the KIT gene occur in 10-22% of mucosal melanomas. Tumor response to imatinib mesylate has been reported in about half of the patients with tumors harboring KIT mutations. Responses are almost exclusively restricted to tumors with mutations in KIT exon 9 or 11. We report a case of a patient with a sinonasal mucosal melanoma with a novel exon 8 mutation (C443S) who had marked initial response to imatinib. Somatic exon 8 KIT mutations have not been previously reported in mucosal melanoma or in other human solid tumors; however, such mutations have been reported in canine and feline mast cell tumors. Protein transcripts from exon 8 play an important role in the structural and functional integrity of the extracellular domain of KIT. In preclinical studies, a mutation in exon 8 led to autophosphorylation, independent of KIT ligand, and constitutive activation of the tyrosine kinase. This biology may explain the successful application of imatinib in animals with tumors harboring exon 8 KIT mutations and in our patient with mucosal melanoma. This report expands the population of patients with melanoma who might benefit from imatinib to those with somatic exon 8 KIT mutations. Such mutations should be looked for in patients with mucosal melanoma. © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins.

Metrics

5 Record Views

Details

Logo image